Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00597311
Other study ID # BE-2-48
Secondary ID 137/2006
Status Recruiting
Phase Phase 3
First received January 9, 2008
Last updated January 9, 2008
Start date January 2007
Est. completion date January 2012

Study information

Verified date January 2008
Source Kaunas University of Medicine
Contact Tadas Latkauskas
Phone +370 676 08901
Email tadas.latkauskas@kmuk.lt
Is FDA regulated No
Health authority Lithuania: Kaunas University of Medicine
Study type Interventional

Clinical Trial Summary

Trial compares two preoperative stage II and III rectal cancer treatment strategies: short term radiotherapy 5x5 Gy and delayed surgery after 6 weeks versus conventional chemoradiotherapy 50 Gy + 5Fu/Lv and surgery also after 6 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- histologically confirmed stage II and III rectal cancer less than 15 cm from anal verge

- less than 80 years old

- no other cancer during 5 years period

- compensate cardiovascular, pulmonary, hepatic and renal functions.

Exclusion Criteria:

- stage I or IV rectal cancer

- other cancer in 5 years period

- radiotherapy or chemotherapy in anamnesis

- not compensate cardiovascular, pulmonary, hepatic or renal functions, neurological, psychiatric disease, sepsis, etc.

- pregnancy or baby feeding

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Radiation:
radiotherapy
Short term radiotherapy 5x5 Gy during 5 days Chemoradiotherapy 50 Gy + 5Fu/Lv

Locations

Country Name City State
Lithuania KMUH, surgery department Kaunas

Sponsors (1)

Lead Sponsor Collaborator
Kaunas University of Medicine

Country where clinical trial is conducted

Lithuania, 

Outcome

Type Measure Description Time frame Safety issue
Primary 5 years overall and disease free survival 5 years Yes
Primary recurrence rate 5 years Yes
Secondary pathological "complete response" and downstaging rates 5 years Yes
Secondary Impact on sphincter sparing operation rates 5 years Yes
Secondary morbidity and mortality rates 5 years Yes
Secondary Impact on quality of surgical resection 5 years Yes